Full-Time
Posted on 7/10/2024
Develops precision oncology treatments for cancer
Junior, Mid
Boston, MA, USA
Scorpion Therapeutics develops precision oncology treatments aimed at targeting specific cancer drivers. Their approach involves creating drugs that interact with validated cancer targets, enhancing their selectivity and safety to improve treatment outcomes. Unlike many competitors, Scorpion Therapeutics focuses on forming partnerships with larger pharmaceutical companies for the distribution of their drugs, allowing them to concentrate on research and development. Their goal is to provide effective cancer therapies that can make a significant impact on patients' lives.
Company Size
51-200
Company Stage
Series C
Total Funding
$408.5M
Headquarters
Boston, Massachusetts
Founded
2020
Help us improve and share your feedback! Did you find this helpful?
In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.
Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding
Streit joined Scorpion in 2022 from Sanofi, where he had most recently served as vice president and senior project head.
Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.
Scorpion Therapeutics appoints precision medicine leader Jeff Albers as strategic advisor.